CN1185953A - Eye drop containing rich oxygen and preparation thereof - Google Patents

Eye drop containing rich oxygen and preparation thereof Download PDF

Info

Publication number
CN1185953A
CN1185953A CN96116645A CN96116645A CN1185953A CN 1185953 A CN1185953 A CN 1185953A CN 96116645 A CN96116645 A CN 96116645A CN 96116645 A CN96116645 A CN 96116645A CN 1185953 A CN1185953 A CN 1185953A
Authority
CN
China
Prior art keywords
oxygen
sod
taurine
edta
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN96116645A
Other languages
Chinese (zh)
Inventor
刘伟中
梁一民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN96116645A priority Critical patent/CN1185953A/en
Publication of CN1185953A publication Critical patent/CN1185953A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

An oxygen-enriched eye drops is an aqueous solution with oxygen content of 25-30 mg/l, which contains such components (mg/ml) as sodium chloride (5-7), boric acid (0-2.5), borax (0-1), Na2HP (0-1.5), NaH2PO (0-1.8), polyoxyethylene-polyoxypropylene block copolymer (3-7), TW-80 (0-4.5), PVP (0-9.5), hydroxymethylpropyl cellulose (0-9), hydroxyethylcellulose (0-3.5), taurine (0-3), borneol (1.5-2), EDTA-Na2 (0-1.2), sorbic acid (0-0.6), SOD (0-2.5) and perfluorane (0-2.8).

Description

Oxygen enrichment easypro eye liquid and production technology thereof
The present invention relates to a kind of easypro eye liquid and production technology thereof, be specifically related to a kind of oxygen enrichment easypro eye liquid and production technology thereof.
As everyone knows, popular in the market contact lens care solution, only be a kind of lens care product that when eyeglass is in non-working condition, uses, and can not in time the eyeglass situation in the use be improved or help, so can not moisten and nutrition to eyes.
The object of the present invention is to provide the practical problem of a kind of effective solution cornea anoxia and eyeglass cleaning in wearing the mirror process, to promote the metabolism of cornea tissue, provide eyes nutrition, anti-eye strain and the improvement oxygen enrichment easypro eye liquid and the production technology thereof of eye situation.
Above-mentioned purpose of the present invention realizes in the following manner: a kind of oxygen enrichment eye liquid that relaxes, by comprising that every milliliter of oxygen content is the component that contains following mg weight in the aqueous solution of 25mg/L-30mg/L:
Sodium chloride 5.0-7.0
Boric acid 0-2.5
Borax 0-1.0
Sodium dihydrogen phosphate 0-1.8
Sodium hydrogen phosphate 0-1.5
*POLOXAMER407??????3.0-7.0
TW-80???????????????0-4.5
**PVP??????????????0-9.5
Hydroxymethyl-propyl cellulose 0-9.0
Hydroxyethyl-cellulose 0-3.5
Taurine 0-3.0
Borneolum Syntheticum 1.5-2.0
EDTA-Na2????????????0-1.2
Sorbic acid 0-0.6
SOD 0-2.5 and
C 4-C 16Perfluor alkane 0-2.8.* be polyox-yethylene-polyoxypropylene block copolymer.* is a polyvinyl pyrrolidone.
The production technology of the easypro eye of a kind of oxygen enrichment liquid, comprise and to be selected from a kind of following formula constituent by being dissolved in water, leaving standstill, filtering, it is 99.99% oxygen that filtrate feeds purity, the control oxygen flow is at 1.5 liters/minute, be 〉=25mg/l that the formula ratio of described component (mg/ml) is selected from following prescription until the aqueous solution oxygen content:
Sodium chloride 5.0-7.0
Boric acid 0-2.5
Borax 0-1.0
Sodium dihydrogen phosphate 0-1.8
Sodium hydrogen phosphate 0-1.5
POLOXAMER407????????3.0-7.0
TW-80???????????????0-4.5
PVP?????????????????0-9.5
Hydroxymethyl-propyl cellulose 0-9.0
Hydroxyethyl-cellulose 0-3.5
Taurine 0-3.0
Borneolum Syntheticum 1.5-2.0
EDTA-Na2????????????0-1.2
Sorbic acid 0-0.6
SOD 0-2.5 and
C 4-C 16Perfluor alkane 0-2.8.
Advantage of the present invention is tangible, and oxygen enrichment of the present invention relaxes eye liquid except the tax oxygen function of humidification with general eye liquid and uniqueness, also has following six big characteristics or effects:
1. improve the tear oxygen content, alleviate the deficiency of cornea oxygen supply, promote the metabolism of cornea;
2. cleaning eyes and intraocular lens prevent that the contaminated thing of eyeglass from adhering to and corrode.Reduce the injury of foreign body, help the removing of intraocular foreign body eyes;
3. composition is safe and reliable, does not contain eyes or eyeglass are produced the harmful substance of ill effect, so irritated personage also can relievedly use;
4. eyes nutrition is provided, effectively eliminates the eyestrain, delay the aging of eyes, improve with the eye situation;
5. moisten eyes and eyeglass, eliminate the xerophthalmia symptom, promote the tear circulation, stop the water evaporates of eyeglass, improve the comfort that stealthy eyeball mirror is worn usefulness;
6. have good antibiotic, antiinflammatory, analgesic, analgesic activity, can effectively prevent contact lens to wear, simultaneously various conjunctivitis, point-like exfoliation of corneal epithelium be had good preventing and therapeutical effect with the improper and complication that causes (as the limbus of corneae blood vessel hyperplasia, corneal sensation is blunt and macropapillary conjunctivitis GPC etc.);
The oxygen enrichment eye liquid that relaxes can effectively prolong the wearing time of eyeglass, guarantees safe in utilizationly, is widely used in various contact lens wearers' daily nursing and health care.
Oxygen enrichment relax eye liquid person that also is applicable to the twenty-twenty vision or do not wear the contact lens daily profit eye of person and eye care.
The present invention is described in further detail below with reference to specific embodiment.Embodiment 1-8:
1. fill a prescription: (every milliliter contains a milligram number)
Composition Embodiment 1 Embodiment 2 Embodiment 3 Embodiment 4 Embodiment 5 Embodiment 6 Embodiment 7 Embodiment 8
Sodium chloride ????5.63 ????7.12 ????6.35 ????5.10 ????6.68 ????7.43 ????5.19 ????6.33
Boric acid ????1.86 ????1.64 ????1.35 ????2.13 ?????- ?????- ?????- ?????-
Borax ????0.69 ????0.62 ????0.58 ????0.83 ?????- ?????- ?????- ?????-
Sodium dihydrogen phosphate ?????- ?????- ?????- ?????- ????1.35 ????1.65 ????1.36 ????1.35
Sodium hydrogen phosphate ?????- ?????- ?????- ?????- ????1.24 ????1.32 ????1.25 ????1.24
???? *POLOXAMER407 ????3.51 ????5.12 ????6.10 ????6.25 ????3.12 ????3.45 ????6.50 ????5.14
????TW-80 ????2.56 ????1.23 ?????- ?????- ????4.26 ????1.36 ?????- ?????-
???? **PVP ?????- ?????- ????8.15 ????6.12 ?????- ????6.38 ?????- ????9.32
Hydroxymethyl-propyl cellulose ????7.50 ????5.23 ?????- ????2.15 ????5.36 ?????- ????8.64 ?????-
Hydroxyethyl-cellulose ?????- ?????- ?????- ?????- ????2.69 ????3.47 ?????- ?????-
Taurine ????2.00 ????2.00 ????2.50 ?????- ????2.65 ????2.00 ?????- ????2.00
Borneolum Syntheticum ????1.65 ????1.50 ????2.50 ????1.50 ????1.60 ????1.80 ????1.60 ????2.00
????EDTA-Na2 ????1.00 ????1.00 ????1.00 ?????- ????1.00 ?????- ?????- ????1.20
Sorbic acid ????0.56 ????0.56 ????0.56 ?????- ????0.56 ????0.56 ?????- ????0.56
????SOD ????0.10 ????0.10 ?????- ????0.10 ?????- ????0.25 ????0.25 ?????-
????C 4-C 16Perfluor alkane ????1.80 ????2.65 ?????- ????0.52 ????1.80 ?????- ????1.85 ?????-
* be polyox-yethylene-polyoxypropylene block copolymer.* is a polyvinyl pyrrolidone.
2. production technology and manufacture process:
(1) dissolving, mixing
Each component (in weight in grams) in the embodiment 1-8 prescription is dissolved in 1000 ml waters, and dissolving is improved after-filtration and is removed behind the insoluble matter stand-byly, changes filtrate over to the oxygen supplement still.
(2) logical oxygen: by at the bottom of the oxygen supplement still in solution slowly bubbling to feed purity be 99.99% oxygen 60 minutes, the control flow is at 1.5 liters/minute, total feeding amount of oxygen is reached more than the 25mg/l, treat that (at this moment still was pressed and reached 1.5kg/cm after theoretical feeding amount surpassed index 10% 2), leaving standstill 30 minutes, sample analysis solution oxygen concentration index enters down the road packaging process after qualified.
Quality standard:
(1) outward appearance: blue, transparent, liquid juice.
(2) pH value: 7.2-7.8
(3) osmotic pressure: 290-310 MOSM/HG
(4) viscosity: be equivalent to the 1%PVA aqueous solution.
(5) Bacteria Detection: qualified (aseptic).
(6) oxygen content: " 25mg/l
(7) eye dripping effect: comfortable, refrigerant, the sensation that makes eye bright is arranged.
The foregoing description only for illustrative purposes, protection scope of the present invention will embody in claims.

Claims (5)

1. the oxygen enrichment eye liquid that relaxes is characterized in that every milliliter of oxygen content is the component that contains following milligram weight in the aqueous solution of 25-30mg/l:
Sodium chloride 5.0-7.0
Boric acid 0-2.5
Borax 0-1.0
Sodium dihydrogen phosphate 0-1.8
Sodium hydrogen phosphate 0-1.5
POLOXAMER407???????3.0-7.0
TW-80??????????????0-4.5
PVP????????????????0-9.5
Hydroxymethyl-propyl cellulose 0-9.0
Hydroxyethyl-cellulose 0-3.5
Taurine 0-3.0
Borneolum Syntheticum 1.5-2.0
EDTA-Na2???????????0-1.2
Sorbic acid 0-0.6
SOD 0-2.5 and
C 4-C 16Perfluor alkane 0-2.8.
2. the oxygen enrichment as claimed in claim 1 eye liquid that relaxes is characterized in that containing in per 1 ml water solution the component of following milligram weight:
Sodium chloride 5.60-7.10
Boric acid 1.60-1.80
Borax 0.6-0.70
*POLOXAMER407??????3.50-5.20
TW-80???????????????1.20-2.60
Hydroxymethyl-propyl cellulose 5.20-7.50
Taurine 2.00
Borneolum Syntheticum 1.50-1.65
EDTA-Na2????????????1.00
Sorbic acid 0.56
SOD?????????????????0.10
C 4-C 16Perfluor alkane 1.8-2.65.
3. the oxygen enrichment as claimed in claim 1 eye liquid that relaxes is characterized in that containing in every ml water solution the component of following milligram weight:
Sodium chloride 5.00-6.50
Boric acid 1.30-2.20
Borax 0.5-0.90
POLOXAMER407????????6.00-6.50
PVP?????????????????6.00-8.20
Hydroxymethyl-propyl cellulose 0-2.20
Taurine 0-2.50
Borneolum Syntheticum 1.50
EDTA-Na2????????????0-1.00
Sorbic acid 0-0.56
SOD 0-0.10 and
C 4-C 16Perfluor alkane 0-0.52.
4. the oxygen enrichment as claimed in claim 1 eye liquid that relaxes is characterized in that containing in every ml water solution the component of following milligram weight:
Sodium chloride 5.00-7.50
Sodium dihydrogen phosphate 1.30-1.70
Sodium hydrogen phosphate 1.20-1.40
POLOXAMER407???????3.00-6.50
TW-80??????????????0-4.30
PVP????????????????0-9.40
Hydroxymethyl-propyl cellulose 0-8.64
Hydroxyethyl-cellulose 0-3.50
Taurine 0-2.65
Borneolum Syntheticum 1.6-2.00
EDTA-Na2???????????0-1.20
Sorbic acid 0.56
SOD????????????????0-0.25
C 4-C 16Perfluor alkane 0-1.85.
5. the oxygen enrichment production technology of eye liquid of relaxing is characterized in that and will be selected from least a (in the weight in grams) of following prescription:
Sodium chloride 5.0-7.0
Boric acid 0-2.5
Borax 0-1.0
Sodium dihydrogen phosphate 0-1.8
Sodium hydrogen phosphate 0-1.5
POLOXAMER407???????3.0-7.0
TW-80??????????????0-4.5
PVP????????????????0-9.5
Hydroxymethyl-propyl cellulose 0-9.0
Hydroxyethyl-cellulose 0-3.5
Taurine 0-3.0
Borneolum Syntheticum 1.5-2.0
EDTA-Na2???????????0-1.2
Sorbic acid 0-0.6
SOD 0-2.5 and
C 4-C 16Perfluor alkane 0-2.8 adds that 1000 ml waters dissolve, leave standstill, to feed oxygen purity be 99.99% oxygen for filtration, filtrate, and the control oxygen flow is at 1.5 liters/minute, be 〉=25mg/l to bottle then until the oxygen content of aqueous solution.
CN96116645A 1996-12-27 1996-12-27 Eye drop containing rich oxygen and preparation thereof Pending CN1185953A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN96116645A CN1185953A (en) 1996-12-27 1996-12-27 Eye drop containing rich oxygen and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN96116645A CN1185953A (en) 1996-12-27 1996-12-27 Eye drop containing rich oxygen and preparation thereof

Publications (1)

Publication Number Publication Date
CN1185953A true CN1185953A (en) 1998-07-01

Family

ID=5123734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN96116645A Pending CN1185953A (en) 1996-12-27 1996-12-27 Eye drop containing rich oxygen and preparation thereof

Country Status (1)

Country Link
CN (1) CN1185953A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1312380A4 (en) * 2000-06-19 2003-08-06 Santen Pharmaceutical Co Ltd Aseptics
EP1586307A2 (en) * 2004-03-23 2005-10-19 Beiersdorf AG Cosmetic or pharmaceutical compositions containing preserved taurine
AU2003297511B2 (en) * 2002-12-20 2010-01-21 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
CN103372230A (en) * 2012-04-12 2013-10-30 启东钛力眼镜制品有限公司 Contact lens care solution
CN103394077A (en) * 2010-06-25 2013-11-20 杨红宇 Eye drop
CN103732202A (en) * 2011-07-26 2014-04-16 阿勒根公司 Two part formulation system for ophthalmic delivery
CN106176593A (en) * 2016-08-29 2016-12-07 安徽艾珂尔制药有限公司 A kind of eye drip Rimactane and preparation method thereof
CN110200015A (en) * 2019-05-21 2019-09-06 何凡 Antiviral biological peptide conditioning liquid of one kind and its preparation method and application

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1312380A4 (en) * 2000-06-19 2003-08-06 Santen Pharmaceutical Co Ltd Aseptics
AU2003297511B2 (en) * 2002-12-20 2010-01-21 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
EP1586307A2 (en) * 2004-03-23 2005-10-19 Beiersdorf AG Cosmetic or pharmaceutical compositions containing preserved taurine
CN103394077A (en) * 2010-06-25 2013-11-20 杨红宇 Eye drop
CN103732202A (en) * 2011-07-26 2014-04-16 阿勒根公司 Two part formulation system for ophthalmic delivery
US9616017B2 (en) 2011-07-26 2017-04-11 Allergan, Inc. Two part formulation system for ophthalmic delivery
US10314887B2 (en) 2011-07-26 2019-06-11 Allergan, Inc. Two part formulation system for ophthalmic delivery
CN103372230A (en) * 2012-04-12 2013-10-30 启东钛力眼镜制品有限公司 Contact lens care solution
CN106176593A (en) * 2016-08-29 2016-12-07 安徽艾珂尔制药有限公司 A kind of eye drip Rimactane and preparation method thereof
CN110200015A (en) * 2019-05-21 2019-09-06 何凡 Antiviral biological peptide conditioning liquid of one kind and its preparation method and application
CN110200015B (en) * 2019-05-21 2020-10-30 乐清市泰博恒电子科技有限公司 Antiviral biological peptide care solution and preparation method and application thereof

Similar Documents

Publication Publication Date Title
EP0799615B1 (en) Liposome eye drops
CN111991415B (en) Eye care composition and preparation method and application thereof
CN1185953A (en) Eye drop containing rich oxygen and preparation thereof
CN108853016A (en) A kind of ophthalmic solution sodium eye drops and preparation method thereof
KR20010020438A (en) Pourable alginate compositions
CN106512062A (en) Multifunctional contact lenses care solution and preparation method thereof
CN110496215A (en) A kind of aqueous ophthalmic solution and preparation method thereof for treating presbyopia
CN101278908B (en) Eye drop capable of significantly increasing medicament effect
CN1943650A (en) Rose liquid and its eye drops
RU2295331C2 (en) Ocular drops with reparative and anti-glaucoma action
CN1237978C (en) Composite eye-moistening liquid and its application
CN115068595A (en) Anti-radiation composition for eyes and preparation method and application thereof
CN1424043A (en) Kakonein eye drops
WO1991017469A1 (en) Kit for contact lenses
CN1215588A (en) Multifunctional health eye moistening atriphos liquid and preparing method thereof
CN103394077A (en) Eye drop
CN1879651A (en) Eye drop containing micro-elements and preparation method thereof
CN1351867A (en) Levo-potasisum magnesium asparate infusion injection and preparing method
US20080152669A1 (en) Method of Stimulating the Production of Mucin in the Eye of a Patient
CN1132574C (en) Eye medicine prepn. for computer eyesight syndrome and xerophthalmia
CN1247264C (en) Nursing liquor for contact lenses and its production process
JP5477798B2 (en) Eye drops for contact lenses containing a cooling agent
CN100522181C (en) Anoxia and fatigue-resisting health-care oxygen, its preparation and use as health-care product
CN1395959A (en) Eyedrops 'Yanbijing'
CN111588693A (en) Cromolyn sodium eye drops and preparation method thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication